SecBot SecBot

BMY

BRISTOL MYERS SQUIBB CO
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0000014272 Biotech & Drug Discovery
$62.93 −0.50 (−0.79%)
Nov 16 4:00 PM ET · prev $63.43
Market cap
$127.5B
Large cap
Consensus
Buy
41% Buy or better · 34 analysts
Median target
🔒 Subscribers only
1 year
+34.4%
from $46.81 · Nov 17
30 days
+7.0%
from $58.83
52-week range
$45.79–68.09
−8% from high · low Nov 19
Avg volume 20D
10.04M
shares / day
Short interest
46.85M
≈2.3% of shares · −6.2%
Days to cover
4.2
at average volume
Insider net
−$2.5M
0 buyers · 4 sellers · since Mar 10
New fund stakes
0
Q2 2026 13F · 4 exits
Reddit crowd
50°
Neutral · 2 mentions this week
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/4 ·Next FDA decision date, Mar 11, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $2.5M.

  • InstitutionsBULLISH

    Q2 2026: 52 added (0 new), 32 trimmed or exited.

  • AnalystsBULLISH

    14 of 34 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −6.2% to 46.85M shares. 4.2 days to cover, ≈2.3% of shares.

  • TrendUPTREND

    2% above its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 2 mentions: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q2 2026
0
new positions
4
exits
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED31,707,643$1.8B
FMR LLCADD16,293,303$938.8M
Allianz Asset Management GmbHADD11,363,537$654.8M
NORDEA INVESTMENT MANAGEMENT ABDOUBLED8,052,294$462.9M
Capital International InvestorsTRIM5,913,752$340.8M
CAISSE DE DEPOT ET PLACEMENT DU QUEBECDOUBLED4,228,503$243.6M
WELLINGTON MANAGEMENT GROUP LLPTRIM3,914,086$225.5M
Employees Provident Fund BoardADD3,640,333$209.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

34 analysts
Buy 41% rate it Buy or better
Strong Buy6Buy8Hold19Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 30, 2026Morgan Stanley
MAINTAIN
MAINTAINUnderweight
Oct 26, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Oct 13, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 8, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINNeutral
Oct 7, 2026Morgan Stanley
MAINTAIN
MAINTAINUnderweight
Oct 5, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Congressional trades
BMY trades disclosed by members of Congress, with disclosure delay.
3 members · 2 buys / 3 sells
DateMemberType AmountDisclosed
Oct 13, 2026 Ro KhannaDHouse Spouse account · Bristol-Myers Squibb Co BUY $1K–$15K Nov 5, 2026 +23d
Oct 7, 2026 Ro KhannaDHouse Spouse account · Bristol-Myers Squibb Co SELL $1K–$15K Nov 5, 2026 +29d
May 15, 2026 Ro KhannaDHouse Spouse account · Bristol-Myers Squibb Co BUY $1K–$15K Jun 9, 2026 +25d
May 7, 2026 Mike KellyRHouse Spouse account · Bristol-Myers Squibb Co SELL $15K–$50K Jun 11, 2026 +35d
Apr 15, 2025 Tommy TubervilleRSenate Own account · Bristol-Myers Squibb Co SELL $1K–$15K Aug 5, 2026 +477d

Insider ledger

Form 4
$0
bought · 0 insiders
$2.5M
sold · 4 insiders
DateInsiderTypeValue
Nov 5, 2026
Haller Julia A
Director
Nov 5, 2026
SELL$240.6K
Nov 3, 2026
Lenkowsky Adam
EVP, Chief Commercial Officer
Nov 3, 2026
TAX W/H$237.5K
Nov 3, 2026
Lenkowsky Adam
EVP, Chief Commercial Officer
Nov 3, 2026
EXERCISE7,522 sh
Nov 1, 2026
BOERNER CHRISTOPHER S.
Chief Executive Officer
Nov 1, 2026
TAX W/H$107.7K
Nov 1, 2026
Shanahan Karin
EVP, Chief Supply Chain & Ops
Nov 1, 2026
EXERCISE6,281 sh
Nov 1, 2026
BOERNER CHRISTOPHER S.
Chief Executive Officer
Nov 1, 2026
OTHER406 sh
Nov 1, 2026
BOERNER CHRISTOPHER S.
Chief Executive Officer
Nov 1, 2026
EXERCISE2,964 sh
Nov 1, 2026
Shanahan Karin
EVP, Chief Supply Chain & Ops
Nov 1, 2026
TAX W/H$200.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 2 0 in posts · 2 in comments
Recent posts
Recent comments
All social signals and their track records

Short side

FINRA· Oct 30, 2026
46,849,171
shares short
-6.2%
vs prior settlement
4.2
days to cover
≈2.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 6, 2026 SEC
Director Julia A. Haller filed a Form 144 notice of intent to sell 3,800 shares of Bristol Myers Squibb common stock…
144 · Impact 2/10
Nov 5, 2026 Insider
Haller Julia A sold 3,800 shares
Director @ $63.31 ($240.6K)
Nov 3, 2026 Insider
Lenkowsky Adam surrendered for taxes 3,848 shares
EVP, Chief Commercial Officer @ $61.71 ($237.5K)
Nov 3, 2026 Insider
Lenkowsky Adam acquired via exercise 7,522 shares
EVP, Chief Commercial Officer
Oct 29, 2026 SEC
Bristol Myers Squibb reported Q3 2026 revenue of $13.07B (+7% YoY), above the $12.73B consensus, driven by 12% Growth…
8-K · Impact 5/10
Oct 23, 2026 SEC
Four asset managers added BMY positions in Q3 2026, with aggregate buying of $18.3M, while one large holder trimmed…
INST-CLUSTER · Impact 3/10
Oct 13, 2026 Congress
Ro Khanna buy
$1,001 - $15,000 · House
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
21 drugs tracked · Drug pipeline →
Upcoming
Recent

Washington

Corporate Lobbying

89 lobbying filings and 10 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

9 filings · 3 bullish · 1 bearish · 5 neutral
All BMY filing & press-release reports (9)